Enlaza Therapeutics
61 employees
Biotech/Pharma
Series A · $176.0M
Open positions (2)
Company details
Team Size61
IndustryBiotech/Pharma
Funding
Total raised
$176.0M
Last stage
Series A
Investors
Avalon Ventures
Total raised
$176.0M
Last stage
Series A
Investors
Sergio Duron
Ph.D. in organic chemistry from the University of Illinois at Urbana-Champaign. Managing Partner at Avalon BioVentures. Previously CSO and co-founder at Nerio Therapeutics (acquired by Boehringer Ingelheim), Calporta Therapeutics (acquired by Merck), and other Avalon portfolio companies.
LinkedInSanford (Sandy) Madigan
Ph.D. in Genetics from SUNY Stony Brook. Managing Partner at Avalon BioVentures. Previously co-founder and CEO of Nerio Therapeutics (acquired by Boehringer Ingelheim for up to $1.3B) and transacting CEO of Calporta Therapeutics (acquired by Merck for up to $576M).
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.